Platelet REACtivity According to TICagrelor Dose After Transcatheter AorticValve Implantation
Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
The narrowing of the aortic valve, which prevents blood from reaching the entire body
correctly is a common disease in our environment. To correct this problem, many patients
undergo Transcatheter Aortic Valve Implantation (TAVI) according to standard clinical
practice. Patients have to continue with a specific pharmacological treatment (antiplatelet
agents) to avoid possible complications during the first months after the procedure. This
treatment is not yet well established. Current guidelines recommend dual antiplatelet therapy
with Aspirin and Clopidogrel for 3-6 months after TAVI to avoid thromboembolic complications.
But the risk of bleeding events with DAPT in this population is not negligible.
This study aims to determine the degree of response to Ticagrelor 60 mg every 12 hours as a
single antiplatelet strategy in patients who do not achieve an adequate response with
Clopidogrel 75mg every 24 hours. The study will evaluate if patients have an adequate
response to Clopidogrel and if not, then patients will start treatment with Ticagrelor 60 mg
every 12 hours after TAVI and until completing 3 months of treatment.